Daiwa Securities Group Inc. Grows Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Daiwa Securities Group Inc. grew its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 1,508.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,759 shares of the company’s stock after buying an additional 11,028 shares during the period. Daiwa Securities Group Inc.’s holdings in Recursion Pharmaceuticals were worth $116,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of RXRX. China Universal Asset Management Co. Ltd. grew its stake in Recursion Pharmaceuticals by 116.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,237 shares of the company’s stock worth $40,000 after buying an additional 2,817 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in Recursion Pharmaceuticals by 25.4% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 10,123 shares of the company’s stock worth $77,000 after buying an additional 2,050 shares in the last quarter. Private Advisor Group LLC bought a new stake in shares of Recursion Pharmaceuticals in the 3rd quarter worth approximately $79,000. Plancorp LLC bought a new stake in shares of Recursion Pharmaceuticals in the 3rd quarter worth approximately $82,000. Finally, QRG Capital Management Inc. bought a new stake in shares of Recursion Pharmaceuticals in the 3rd quarter worth approximately $86,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Stock Up 3.6 %

NASDAQ:RXRX opened at $8.12 on Friday. The company has a fifty day moving average of $10.37 and a 200 day moving average of $9.13. Recursion Pharmaceuticals, Inc. has a 52 week low of $4.54 and a 52 week high of $16.75. The firm has a market capitalization of $1.91 billion, a P/E ratio of -5.24 and a beta of 0.76.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative net margin of 735.99% and a negative return on equity of 72.88%. The company had revenue of $10.89 million during the quarter, compared to analyst estimates of $12.37 million. As a group, analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.63 EPS for the current year.

Insider Activity at Recursion Pharmaceuticals

In related news, COO Tina Marriott sold 8,000 shares of the company’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $14.89, for a total transaction of $119,120.00. Following the completion of the sale, the chief operating officer now directly owns 639,982 shares in the company, valued at approximately $9,529,331.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Recursion Pharmaceuticals news, COO Tina Marriott sold 8,000 shares of the company’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $14.89, for a total value of $119,120.00. Following the completion of the transaction, the chief operating officer now directly owns 639,982 shares in the company, valued at approximately $9,529,331.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Blake Borgeson sold 20,054 shares of the company’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $12.32, for a total transaction of $247,065.28. Following the completion of the transaction, the director now owns 7,292,863 shares of the company’s stock, valued at $89,848,072.16. The disclosure for this sale can be found here. Insiders sold 348,218 shares of company stock worth $3,536,464 in the last three months. 19.96% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on RXRX shares. KeyCorp boosted their price objective on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a report on Monday, March 4th. TD Cowen started coverage on shares of Recursion Pharmaceuticals in a report on Friday, January 26th. They issued a “market perform” rating for the company. Finally, Needham & Company LLC restated a “buy” rating and issued a $17.00 price objective on shares of Recursion Pharmaceuticals in a report on Tuesday, April 9th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $12.75.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.